Glycemia, Hypoglycemia, and Costs of Simultaneous Islet-Kidney or Islet After Kidney Transplantation Versus Intensive Insulin Therapy and Waiting List for Islet Transplantation. 2015

Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
1 Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Zurich, Switzerland. 2 Division of Transplantation Surgery, University Hospital Zurich, Switzerland. 3 Division of Endocrinology, Diabetology and Osteology, Cantonal Hospital of St. Gallen, Switzerland.

BACKGROUND Long-term data of patients with type 1 diabetes mellitus (T1D) after simultaneous islet-kidney (SIK) or islet-after-kidney transplantation (IAK) are rare and have never been compared to intensified insulin therapy (IIT). METHODS Twenty-two patients with T1D and end-stage renal failure undergoing islet transplantation were compared to 70 patients matched for age and diabetes duration treated with IIT and to 13 patients with kidney transplantation alone or simultaneous pancreas-kidney after loss of pancreas function (waiting list for IAK [WLI]). Glycemic control, severe hypoglycemia, insulin requirement, and direct medical costs were analyzed. RESULTS Glycated hemoglobin decreased significantly from 8.2 ± 1.5 to 6.7 ± 0.9% at the end of follow-up (mean 7.2 ± 2.5 years) in the SIK/IAK and remained constant in IIT (7.8 ± 1.0% and 7.6 ± 1.0) and WLI (7.8 ± 0.8 and 7.9 ± 1.0%). Daily insulin requirement decreased from 0.53 ± 0.15 to 0.29 ± 0.26 U/kg and remained constant in IIT (0.59 ± 0.19 and 0.58 ± 0.23 U/kg) and in WLI (0.76 ± 0.28 and 0.73 ± 0.11 U/kg). Severe hypoglycemia dropped in SIK/IAK from 4.5 ± 9.7 to 0.3 ± 0.7/patient-year and remained constant in IIT (0.1 ± 0.7 and 0.2 ± 0.8/patient-year). Detailed cost analysis revealed US $57,525 of additional cost for islet transplantation 5 years after transplantation. Based on a 5- and 10-year analysis, cost neutrality is assumed to be achieved 15 years after transplantation. CONCLUSIONS This long-term cohort with more than 7 years of follow-up shows that glycemic control in patients with T1D after SIK/IAK transplantation improved, and the rate of severe hypoglycemia decreased significantly as compared to control groups. Cost analysis revealed that islet transplantation is estimated to be cost neutral at 15 years after transplantation.

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005260 Female Females

Related Publications

Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
August 2008, Current diabetes reports,
Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
January 2010, Nutricion hospitalaria,
Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
January 2018, Current transplantation reports,
Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
January 2019, Journal of diabetes research,
Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
August 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
January 2011, Transplantation proceedings,
Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
October 1989, Bailliere's clinical gastroenterology,
Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
September 2009, Transplantation,
Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
January 2005, Transplantation proceedings,
Philipp A Gerber, and Rebecca Locher, and Richard A Zuellig, and Oliver Tschopp, and Evelyne Ajdler-Schaeffler, and Philipp Kron, and Christian Oberkofler, and Michael Brändle, and Giatgen A Spinas, and Roger Lehmann
January 2013, Bratislavske lekarske listy,
Copied contents to your clipboard!